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ABSTRACT  
Objective: Left ventricular (LV) global longitudinal strain (GLS) reflects LV systolic function 
and correlates inversely with the extent of LV myocardial scar and fibrosis. The present 
subanalysis of the EchoCRT trial investigated the prognostic value of LV GLS in patients with 
narrow QRS complex. 
Methods and results: LV GLS was measured on the apical 2-, 4- and 3-chamber views using 
speckle tracking analysis. Measurement of baseline LV GLS was feasible in 755 patients (374 
with CRT-ON and 381 with CRT-OFF). The median value of LV GLS in the overall population 
was 7.9%, interquartile range 6.2-10.1%. After a mean follow-up period of 19.4 months, 95 
patients in the CRT-OFF group and 111 in the CRT-ON group reached the combined primary 
endpoint of.all-cause mortality and heart failure hospitalization. Each 1% absolute unit 
decrease in LV GLS was independently associated with 11% increase in the risk to reach the 
primary endpoint (hazard ratio 1.11; 95% confidence interval 95% 1.04-1.17, P<0.001), after 
adjusting for ischemic cardiomyopathy and randomization treatment among other clinically 
relevant variables. When categorising patients according to quartiles of LV GLS, the primary 
endpoint occurred more frequently in patients in the lowest quartile (<6.2%) treated with 
CRT-ON versus CRT-OFF (45.6% versus 28.7%, P=0.009) whereas no differences were 
observed in patients with LV GLS ≥6.2% treated with CRT-OFF versus CRT-ON (23.7% versus 
24.5%, respectively; P=0.62). 
Conclusion: Low LV GLS is associated with poor outcome in heart failure patients with  QRS 
width <130 ms, independent of randomisation to  CRT or not. Importantly, in the group of 
patients with the lowest LV GLS quartile, CRT may have a detrimental effect on clinical 
outcomes. 
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INTRODUCTION 
Cardiac resynchronization therapy (CRT) is an established treatment for heart failure 
patients with reduced left ventricular ejection fraction (LVEF) and wide QRS complex who 
remain symptomatic despite optimal medical treatment.1, 2 The presence of extensive scar 
tissue in the left ventricle (LV) (in patients with ischemic cardiomyopathy) or significant 
replacement fibrosis (in patients with non-ischemic cardiomyopathy), however, limits the 
response to CRT.3-6 While late-gadolinium contrast enhanced cardiac magnetic resonance 
(CMR) provides the highest spatial resolution to quantify the extent of scar tissue and 
fibrosis,7 echocardiography remains the imaging technique of first choice to evaluate heart 
failure patients considered for CRT in routine clinical practice. In particular, speckle tracking 
echocardiography permits assessment of LV global longitudinal strain (GLS), which reflects 
LV systolic function and inversely correlates with the extent of myocardial scar and fibrosis.8-
10 Since the incremental prognostic value of LV GLS over LVEF has been demonstrated in 
heart failure patient,11, 12 LV GLS may be related with prognosis of heart failure patients who 
underwent CRT implantation. 
 In 2013, the results of the Echocardiography Guided Cardiac Resynchronization 
Therapy (EchoCRT) study revealed that CRT does not improve outcome of heart failure 
patients with a QRS duration <130 ms and LV mechanical dyssynchrony on 
echocardiography.13 While the exact mechanism underlying non-response remains elusive, 
the individual response (based on improvement in clinical symptoms, LV function or 
prognosis) varied significantly. Intriguingly, the presence and extent of myocardial scar 
and/or replacement fibrosis may be important for patient outcome. As such, the prognostic 
value of LV GLS obtained by speckle tracking echocardiography analysis as an indirect marker 
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of LV myocardial scar and/or fibrosis was analysed in the current substudy of the EchoCRT 
trial. 
 
METHODS 
Study design and patient population 
 Details of the study design and patient characteristics have been previously 
reported.13 In brief, patients (aged 18 years or older) with heart failure symptoms (New York 
Heart Association class III or IV) despite optimal medical therapy, an LVEF ≤35%, a QRS 
duration <130 ms, an LV end-diastolic diameter ≥55 mm, echocardiographic evidence of LV 
dyssynchrony and standard indication for an implantable cardioverter defibrillator (ICD) 
were randomized to CRT-OFF (control group) or CRT-ON.13 Patients presenting with acute 
decompensated heart failure (hemodynamically unstable or need for inotropic support), 
atrial fibrillation within the previous month or bradycardia requiring pacing, were excluded. 
The study protocol was approved by the institutional review board of each participating 
center and all patients gave written informed consent.  
 Biotronik Lumax HF-T CRT devices with defibrillator function were implanted 
conventionally with an atrial and right and left ventricular pacing leads.13 The ICD function 
was programmed on for all patients. In the CRT-ON group, the device programming was set 
to optimize the CRT delivery while, in patients allocated to the CRT-OFF group, the device 
settings were programmed to minimize right ventricular pacing. Device-implanting 
physicians and physicians involved in the follow-up were aware of the study-group 
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assignment whereas patients, heart-failure physicians and study personnel completing the 
follow-up assessments were not. 
Echocardiography and global left ventricular longitudinal strain 
 Transthoracic echocardiography data were acquired according to specific protocol 
described previously using a uniform ultrasound platform (GE Vivid 7 or E9, Horton, 
Norway).13 Off-line echocardiographic data analysis was performed following the American 
Society of Echocardiography and the European Association of Cardiovascular Imaging 
recommendations using uniform software (GE EchoPAC version BT11-12, Horton, Norway).14 
Data analysis was performed at a core laboratory (University of Pittsburgh, 
Echocardiography Core Laboratory, Pittsburgh, PA, USA) by investigators blinded to 
randomization and all other clinical data. From the parasternal long-axis view, the LV end-
diastolic diameter was measured. The LV end-diastolic and end-systolic volumes were 
measured on the apical 2- and 4-chamber views and the LVEF was calculated according to 
the Simpson’s method. Left ventricular dyssynchrony was assessed with color-coded tissue 
Doppler imaging data from the apical 4- and 3-chamber views and speckle-tracking 
echocardiography data from the parasternal mid-ventricular short-axis and quantified as the 
time difference in peak systolic velocity of two opposing walls and the time difference 
between peak radial strain of the anteroseptal and posterior segments, respectively.13  
 Global LV longitudinal strain was assessed from 2-dimensional LV apical 4-, 2- and 3-
chamber views. The region of interest in each apical view was set by tracing manually the 
endocardial border. The software displayed automatically an epicardial tracing to include the 
entire myocardial width. The width of the region of interest could be modified manually to 
ensure inclusion of the myocardial wall. Subsequently, the software tracked frame by frame 
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the speckles included in the region of interest and provided a track quality which can be 
approved or rejected by the observer. The software provides the magnitude of longitudinal 
strain of 6 segments in each LV apical view and the magnitude of LV GLS strain is calculated 
as the average of 18 segmental strain values (Figure 1). Global LV longitudinal strain is 
presented in absolute value. The intraclass correlation coefficient was used to assess the 
inter- and intraobserver reproducibility from 15 randomly selected patients using the same 
cine-loop for each view. The intra-class correlation coefficient for LV GLS for intra- and 
interobserver variability were 0.97 (95% CI 0.93-0.99) and 0.92 (95% CI 0.72-0.98) 
respectively. 
Study endpoint 
 Patients were followed up for the occurrence of all-cause mortality or hospitalization 
for worsening heart failure, as reported previously.13 Additional pre-specified endpoints of 
the EchoCRT trial included the occurrence of arrhythmias defined by appropriate ICD 
therapy for ventricular arrhythmias, arrhythmic death and atrial tachyarrhythmia events. 
These events were adjudicated by an independent committee. 
Statistical analysis  
 The statistical analysis was performed at the Robertson Center for Biostatistics at the 
University of Glasgow as previously reported.13 Analyses were performed by intention-to-
treat. Continuous variables were presented as mean with standard deviation and compared 
using two-sample t-tests. Categorical variables were presented as counts and percentages 
and compared using chi-square tests. To investigate the association of LV GLS with clinical 
outcome after adjustment for key covariates, Cox proportional hazard models were fitted. 
Hazard ratios (HRs) and the 95% confidence intervals (CIs) were calculated and adjusted for 
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randomized treatment group, country, age, gender, ischemic cardiomyopathy, QRS duration, 
chronic kidney disease, diabetes, LV end-systolic volume, mitral regurgitation grade and LV 
dyssynchrony measured with speckle tracking echocardiography. To further enhance the 
clinical value of LV GLS, the study population was divided according to the first LV GLS 
quartile and randomized treatment (CRT-ON and CRT-OFF). This exploratory analysis permits 
identification of the subgroup of patients with the worst LV systolic function (lowest LV GLS) 
and evaluation of their outcome according to the randomized treatment. The time to event 
curves were estimated with the Kaplan-Meier method and compared with the log-rank test. 
Follow-up was censored at study closure, date of death, LV assist device implantation, heart 
transplant or withdrawal from the study or loss to follow-up, whichever came first. The 
interaction between LV GLS group and randomized treatment group (CRT-ON and CRT-OFF) 
was tested in a Cox model that included LV GLS group and treatment main effects and 
interaction terms. All tests were two-sided and a p value<0.05 was considered significant. 
 
RESULTS 
Patient characteristics 
 A total of 809 patients were included, with 405 allocated to the CRT-OFF group 
(control) and 404 to the CRT-ON group. The present substudy includes 755 patients (374 in 
the CRT-ON group and 381 in the control group, CRT-OFF) in whom LV GLS analysis was 
feasible. In 54 patients, LV GLS analysis was not feasible due to image quality. The baseline 
clinical and echocardiographic characteristics are displayed in Table 1.  
Impact of global LV longitudinal strain on prognosis 
9 
 
 After a mean follow-up period of 19.4 months, 95 patients in the CRT-OFF group and 
111 in the CRT-ON group reached the primary endpoint of all-cause mortality or heart failure 
hospitalization. On multivariable Cox regression analysis for the pooled study groups, LV GLS 
as a continuous variable was associated with the occurrence of the primary endpoint with a 
HR of 1.11 (95% CI 1.04-1.17, P<0.001). Each 1% absolute unit decrease in LV GLS (indicating 
more myocardial scar/fibrosis) was associated with 11% increase in the risk of all-cause 
mortality or heart failure hospitalization (Table 2).  
Characteristics and outcomes of patients according to global LV longitudinal strain quartile  
 The median value of LV GLS in the overall population was 7.9%, interquartile range 
6.2-10.1%. The study population was categorized into two groups according to the first LV 
GLS quartile: patients in the lowest LV GLS group (<6.2%) reflecting more myocardial 
scar/fibrosis and patients with LV GLS ≥6.2%, reflecting less myocardial scar/fibrosis. The 
baseline characteristics of the patients in the lowest LV GLS group compared with patients 
with LV GLS ≥6.2% are presented in the supplementary material. The Kaplan-Meier curves 
show the cumulative event rates of the combined primary endpoint (all-cause mortality or 
hospitalization for worsening heart failure) for patients divided according to LV GLS <6.2% 
(more reduced strain) versus ≥6.2% (less reduced strain), reflecting more and less 
myocardial scar/fibrosis respectively, and the treatment group (CRT-ON versus CRT-OFF) 
(Figure 2). The interaction between treatment group and LV GLS was not statistically 
significant; however, as this test was inadequately powered, the prognostic influence of CRT-
ON and CRT-OFF on patients with LV GLS<6.2% and patients with LV GLS ≥6.2% was assessed 
in an exploratory analysis. After a mean follow-up period of 19.4 months, 42 (45.65%) 
patients with LV GLS <6.2% who received CRT-ON reached the primary endpoint compared 
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with 27 (28.72%) patients who received CRT-OFF (adjusted HR 2.01, 95% CI 1.19-3.37; 
P=0.009). In contrast, within the group of patients with LV GLS ≥6.2%, the primary endpoint 
occurred in 69 (24.47%) and 68 (23.69%) patients treated with CRT-ON and CRT-OFF 
respectively (adjusted HR 1.09, 95% CI 0.78-1.53; P=0.62). Similar results were observed 
when focusing only on all-cause mortality (Figure 3). 
 In terms of arrhythmic events, 34 (8.9%) patients randomized to CRT-OFF and 38 
(10.1%) randomized to CRT-ON presented with arrhythmic death or arrhythmic events. LV 
GLS was not independently associated with this outcome (HR 1.06, 95% CI 0.89-1.25; 
P=0.51). When comparing patients within the lowest LV GS quartile (<6.2%) versus patients 
with LV GLS ≥6.2%, similar results were observed: the HRs were similar for both groups of 
patients (LV GLS<6.2%: HR 1.44, 95% CI 0.56-3.70; P=0.45; LV GLS ≥6.2%: HR 1.09, 95% CI 
0.63-1.90; P=0.76). 
 
DISCUSSION 
 The present substudy of the EchoCRT trial showed that low LV GLS, reflecting larger 
extent of myocardial scar/fibrosis, is associated with the combined endpoint of all-cause 
mortality or hospitalization for worsening heart failure after adjusting for key covariates. 
This association was modulated by the use of CRT: patients with GLS <6.2% who received 
CRT-ON showed higher risk of the combined endpoint as compared to the other groups. 
 LV GLS versus cardiac fibrosis and scar formation in heart failure  
 Myocardial fibrosis is the hallmark of LV remodelling and functional deterioration in 
heart failure, regardless the underlying etiology.15 Changes in the extracellular matrix with 
increase of the collagen production by fibroblasts and myofibroblasts leads to so-called 
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reactive fibrosis characterized by expansion of the extracellular space. Progressive loss of 
contractile myofilaments and myocytes apoptosis will lead to replacement fibrosis with 
accumulation of type I collagen following a localized (e.g. ischemic cardiomyopathy) or 
diffuse distribution (e.g. inflammatory disease, toxic cardiomyopathy) depending on the 
etiology. Cardiac magnetic resonance is the most accurate method to non-invasively 
evaluate reactive and replacement fibrosis. These structural changes lead to regional and 
global LV dysfunction which can be characterized with speckle tracking echocardiography by 
measuring myocardial strain. LV GLS reflects the shortening of the myocardial fibers in the 
longitudinal direction and also has been inversely correlated with the amount of myocardial 
(diffuse and replacement) fibrosis.9, 10, 16 In heart failure patients undergoing heart 
transplantation, LV GLS was significantly correlated with the amount of LV fibrosis on 
histology (R=0.75, P<0.001).16 Moreover, in patients with ischemic cardiomyopathy, a good 
correlation between LV GLS and the amount of scar tissue on late gadolinium contrast 
enhanced CMR was shown (R=0.62, P<0.001), and a regional value of longitudinal strain 
<4.5% was the optimal cut-off value to identify transmural scar.10 These results support 
these use of LV GLS as surrogate marker of the myocardial fibrosis/scar burden in heart 
failure patients. However, as demonstrated in other studies,10, 16 the correlation between 
the extent of myocardial scar/fibrosis and LV GLS is not straight forward since LV GLS also 
reflects the LV systolic dysfunction caused by multiple factors such as the workload burden 
imposed by the scarred segments onto the viable myocardial segments, LV dyssynchrony or 
loading conditions. 
Prognostic value of LV GLS in heart failure patients  
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 Current guidelines include LVEF as a main parameter for risk stratification of heart 
failure patients.17 However, accumulating evidence has shown that LV GLS has superior 
prognostic value over LVEF to predict all-cause and cardiovascular mortality.11, 12, 18 In a 
recent study evaluating the  prognostic value of LV GLS in 1,065 heart failure patients (43% 
non-ischemic cardiomyopathy), Sengelov et al showed that each 1% decrease in LV GLS was 
independently associated with 1.15-fold increased risk of all-cause mortality (P=0.008).12 
Furthermore, LV GLS was particularly useful in risk stratification of patients with LVEF <22%; 
patients with LV GLS <5.9% showed higher mortality rates as compared with patients with LV 
GLS≥5.9%. This cut-off value is similar to the lowest quartile of the present population 
(6.2%). Similarly, patients with LV GLS <6.2% showed worse outcome than their 
counterparts. 
Interaction between LV GLS and CRT  
 The association between the extent of myocardial scar/fibrosis and CRT efficacy (in 
terms of improvement in LV systolic function and patients prognosis) has been 
demonstrated in various studies.3, 4, 6 In 190 ischemic heart failure patients treated with CRT, 
those with low scar burden on nuclear imaging with thallium-201 had better prognosis and 
improvement in LV systolic function as compared to patients with higher scar burden.3 
Similarly, patients with more scar tissue on delayed-contrast enhanced CMR revealed less LV 
reverse remodelling after CRT.6 
 Two recent studies used LV GLS for prognosis in CRT patients. In a substudy of the 
Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy 
trial, patients with higher LV GLS (above the median value ≥8.7%) showed the greatest 
prognostic benefit from CRT (HR 0.43, 95% CI 0.24-0.77; P=0.005).19 In a retrospective series 
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of 205 patients treated with CRT (70% with left bundle branch block QRS morphology), LV 
GLS <9% was associated with higher rates of all-cause mortality, LV assist device 
implantation and heart transplantation (unadjusted HR 2.91, 95% CI 1.88-4.49, P<0.001).20 
On multivariate analysis, each decrease in LV GLS was associated with 1.11-fold increased 
risk of the combined endpoint (95% CI 1.1-1.23, P=0.032).  
 These results are extended in the current EchoCRT substudy focusing on patients 
with narrow QRS complex: reduced LV GLS (partially reflecting fibrosis and/or scar formation 
or severe LV dysfunction) was associated with worse outcome in patients treated with CRT.  
Two other studies assessed the effect of CRT in patients with narrow QRS complex and scar 
tissue, although these studies focused on patients with recent infarction.21, 22 The Prevention 
of Myocardial Enlargement and Dilation Post Myocardial Infarction (MENDMI) study 21 and 
the Post-Myocardial Infarction Remodelling Prevention Therapy (PRomPT) trial 22 showed 
that pacing close to the infarcted area did not prevent LV dilatation or reduced heart failure 
hospitalization and/or all-cause mortality. The patients included in MENDMI and PROMPT 
differ significantly from the patients in the EchoCRT trial, who presented with more 
advanced LV remodelling and higher burden of LV myocardial scar/fibrosis. Nevertheless, 
these different studies have in common the suggestion that the presence of LV myocardial 
scar/fibrosis limits the efficacy of CRT. In the EchoCRT population, particularly the patients in 
the lowest LV GLS quartile (with the largest extent of myocardial scar/fibrosis and lowest 
contractile function) showed the worst prognosis when treated with CRT-ON, thus 
suggesting that active LV pacing could have an adverse effect. The pathophysiologic 
mechanism underlying this association warrants further evaluation.  
Study limitations 
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 Although LV GLS was associated with worse outcome in the overall population of the 
EchoCRT trial after adjusting for key covariates, the interaction term between randomized 
therapy and LV GLS was not statistically significant probably due to the relatively low 
number of patients with LV GLS<6.2% and events. However, the present substudy should be 
considered as hypothesis generating exploring the effect of CRT in patients with significant 
LV myocardial fibrosis/scar. 
CONCLUSION 
 In heart failure patients with narrow QRS complex, the presence of impaired LV GLS 
is associated with worse outcome independent of randomisation to  CRT or not. Importantly, 
in the group of patients in the lowest LV GLS quartile, CRT may have a detrimental effect on 
clinical outcomes.  
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Table 1. Baseline characteristics of the study population. 
 N = 755 
Age (years) 58.5±12.5 
Male sex – n (%) 547 (72.45) 
Ischemic cardiomyopathy – n (%) 413 (54.77) 
QRS duration (ms) 105.7±12.68 
Walking distance (m) 325.5±121.29 
Quality-of-life score 50.7±24.35 
NYHA classification – n (%) 
I-II 
III-IV 
 
23 (3.05) 
732 (96.95) 
Hypertension – n (%) 496 (66.31) 
Diabetes mellitus – n (%) 300 (39.89) 
Chronic kidney disease – n (%) 103 (13.75) 
LVESV (ml) 138.8±49.82 
LVEDV (ml) 188.0±59.06 
LVEF (%) 27.0±5.49 
Mitral regurgitation grade – n (%) 
0-2 
3-4 
 
670 (89.69) 
77 (10.31) 
TDI dyssynchrony (ms) 101.2±34.68 
Speckle tracking radial dyssynchrony (ms) 217.2±102.28 
Global LV longitudinal strain (%) 8.2±2.83 
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Medication – n (%) 
Beta-blocker 
ACE inhibitor or ARB 
Diuretic 
Aldosterone antagonist 
 
728 (96.42) 
719 (95.23) 
650 (86.09) 
451 (59.74) 
 
Abbreviations: ACE: angiotensin-converter enzyme; ARB: angiotensin receptor blocker; LV: 
left ventricular; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection 
fraction; LVESV: left ventricular end-systolic volume; NYHA: New York Heart Association; TDI: 
tissue Doppler imaging. For continuous variables the mean and standard deviation are 
presented.
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Table 2. Uni- and multivariable Cox proportional hazard models for all-cause mortality or heart failure hospitalization.  
 Univariable Multivariable 
HR (95% CI) P-value HR (95%CI) P-value 
Age (years) 0.99 (0.94-1.05) 0.780 0.98 (0.91-1.04) 0.485 
Male gender  0.90 (0.66-1.21) 0.478 0.79 (0.56-1.12) 0.187 
Ischemic cardiomyopathy 1.12 (0.85-1.48) 0.427 1.21 (0.87-1.68) 0.251 
QRS duration (per 10 ms increase) 1.09 (0.98-1.21) 0.100 1.07 (0.94-1.21) 0.325 
Chronic kidney disease 1.68 (1.19-2.38) 0.003 1.34 (0.91-1.96) 0.136 
Diabetes mellitus 1.77 (1.34-2.33) <0.001 1.59 (1.19-2.13) 0.002 
LVESV (per 10 mL increase) 1.03 (1.00-1.05) 0.043 1.00 (0.96-1.03) 0.822 
Mitral regurgitation grade (3-4) 2.04 (1.38-3.01) <0.001 1.98 (1.31-2.99) 0.001 
Speckle tracking echocardiography radial strain LV 
dyssynchrony  (per 10 ms increase) 
1.00 (1.00-1.00) 0.434 1.00 (1.00-1.00) 0.780 
Global LV longitudinal strain (per 1% decrease in 
magnitude)  
1.14 (1.07-1.20) <0.001 1.11 (1.04-1.17) <0.001 
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Randomization group CRT-ON 1.26 (0.96-1.66) 0.098 1.19 (0.89-1.58) 0.238 
 
Abbreviations: CI: confidence interval; CRT: cardiac resynchronization therapy; HR: hazard ratio; LV: left ventricular; LVESV: left ventricular end-
systolic volume. 
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Figure 1. Assessment of global left ventricular longitudinal strain with speckle tracking 
echocardiography. Example of a patient with ischemic heart failure (inferior myocardial 
infarction). From the apical 4-, 2- and long-axis (APLAX) views, the longitudinal strain curves 
are displayed for 18 segments. The global longitudinal strain value is calculated as the 
average of the peak systolic strain of the 18 segments. The bull’s-eye plot shows more 
impaired longitudinal strain in the inferoposterior segments (blue color) concordant with 
previous inferior myocardial infarction. 
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Figure 2. Kaplan Meier estimates for cumulative event rates of the combined primary 
endpoint (all-cause mortality or hospitalization for worsening heart failure) for patients 
divided according to the extent global LV longitudinal strain <6.2% (more reduced strain) 
versus ≥6.2% (less reduced strain) and the treatment group (CRT-ON versus CRT-OFF). 
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Figure 3. Kaplan Meier estimates for cumulative event rates of all-cause mortality for 
patients divided according to the extent global LV longitudinal strain <6.2% (more reduced 
strain) versus ≥6.2% (less reduced strain) and the treatment group (CRT-ON versus CRT-
OFF). 
 
 
 
 
